Journal Article
Multicenter Study
Add like
Add dislike
Add to saved papers

Thrombocytopenia following timber rattlesnake envenomation.

STUDY OBJECTIVE: To better characterize timer rattlesnake venom--induced thrombocytopenia and coagulopathy and the response to therapy with Antivenin (Crotalidae) Polyvalent.

METHODS: We conducted a retrospective multicenter review of timber rattlesnake envenomation.

RESULTS: We reviewed 18 cases at two institutions. Restoration of normal prothrombin time and partial thromboplastin time was achieved in all cases with antivenom therapy. In contrast, complete reversal of thrombocytopenia was not achieved, despite antivenom therapy.

CONCLUSION: Antivenom (Crotalidae) Polyvalent was less effective in reversing thrombocytopenia than coagulopathy after timber rattlesnake envenomation, suggesting that a component of timber rattlesnake venom persists in the blood despite antivenom therapy. Persistent thrombocytopenia may be due to a venom factor that the antivenom does not neutralize or to inadequate dosing of antivenom. Prompt reversal of thrombocytopenia following treatment of timber rattlesnake envenomation with this antivenom appears unlikely.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app